New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Gold nanoparticles show new way to kill lymphoma without chemotherapy
How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.
Cancer
Jan 21, 2013 |
4.9 / 5 (15) |
1
|
Study finds how to shutdown cancer's powerful master protein
The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Immunology
Mar 03, 2013 |
5 / 5 (6) |
0
|
Genome sequencing of Burkitt Lymphoma reveals unique mutation
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and ...
Genetics
Nov 12, 2012 |
5 / 5 (1) |
0
|
Solving puzzle of B-cell lymphoma development
Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce ...
Immunology
Sep 23, 2012 |
4.9 / 5 (7) |
0
|
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer
May 01, 2013 |
not rated yet |
0
Immunotherapy showed promising antileukemia activity in pediatric patients
Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned ...
Cancer
Apr 07, 2013 |
5 / 5 (1) |
0
Antibodies to intracellular cancer antigens combined with chemotherapy enhance anti-cancer immunity
An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune system's ability to find and eliminate cancer ...
Cancer
Feb 13, 2012 |
5 / 5 (1) |
0
Scientists identify new target for lung cancer treatment
A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed ...
Cancer
Nov 01, 2012 |
4 / 5 (1) |
0
|
Discovery of new class of damage-prone DNA regions could lead to better cancer treatments
Cancer is thought to arise from DNA damage at fragile sites in the genome. A study published by Cell Press on January 24th in the journal Cell reveals a new class of fragile sites that contributes to DNA ...
Cancer
Jan 24, 2013 |
5 / 5 (1) |
0
|
Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
Many observational epidemiologic studies have found an inverse association between alcohol consumption and hematological cancers (such as lymphoma and leukemia). This study, based on the Million Women's Study in the UK, is ...
Cancer
Nov 13, 2012 |
not rated yet |
0
B cell survival holds key to chronic graft vs. host disease
Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and ultimately affect their ...
Diseases, Conditions, Syndromes
Aug 16, 2012 |
not rated yet |
0
|
New key element discovered in pathogenesis of Burkitt lymphoma
Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine ...
Cancer
Aug 13, 2012 |
5 / 5 (1) |
0
|
Mutation ID'd in Waldenstrom's macroglobulinemia
(HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.
Cancer
Aug 30, 2012 |
not rated yet |
0
Protein may represent a switch to turn off B cell lymphoma
Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain ...
Cancer
May 07, 2012 |
5 / 5 (1) |
0
